AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27161974 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of adjuvant tamoxifen (n = 276)
Number of subjects: 564
Study 27161974 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment (n = 288)
Number of subjects: 564
Study 25126866 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking awareness programme (health talks, information leaflets, and posters)
Number of subjects: 0
Study 25126866 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking awareness programme
Number of subjects: 0
Study 22446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 420
Study 22446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 420
Study 22446170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus pioglitazone
Number of subjects: 420
Study 22446170 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone alone
Number of subjects: 420
Study 22446170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 420
Study 22446170 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pioglitazone
Number of subjects: 420
Study 20181810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary products (resveratrol, green tea extract, alpha-tocopherol, vitamin C, n-3 polyunsaturated fatty acids, tomato extract)
Number of subjects: 36
Study 18086740 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine interview (TM)
Number of subjects: 21
Study 18086740 — intervention group
Group type: COMPARATOR
Intervention: Live interview (LI)
Number of subjects: 21
Study 21213495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg per oral three times a day for 5 days
Number of subjects: 50
Study 21213495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11715356 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 11715356 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral endopeptidase inhibitors (in combination with ACE inhibitors)
Number of subjects: 0
Study 11715356 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 antagonists
Number of subjects: 0
Study 9642622 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer-1
Number of subjects: 251
Study 9642622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 7626915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bimakalim (cumulative doses of 10, 25, 40, and 100 micrograms, total cumulative dose 175 micrograms)
Number of subjects: 12
Study 7626915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2510115 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG Cutter 0.6 mg per Kg BW per week
Number of subjects: 35
Study 2510115 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 infants with similar criteria)
Number of subjects: 35
Study 825821 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral supplementation with dextrose and amino acids (67 cal/dl formula feeding)
Number of subjects: 10
Study 825821 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding (100 cal/dl formula feeding)
Number of subjects: 10
Study 825821 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral supplementation
Number of subjects: 10
Study 31222434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque-induced gingivitis group
Number of subjects: 22
Study 31222434 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 30677539 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 29
Study 29049577 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce inappropriate antibiotic prescribing
Number of subjects: 0
Study 26555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of danoprevir (100 mg three times daily) and mericitabine (500 mg twice daily)
Number of subjects: 72
Study 26555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of danoprevir (600 mg twice daily) and mericitabine (1,000 mg twice daily)
Number of subjects: 72
Study 26555159 — intervention group
Group type: COMPARATOR
Intervention: Combination of mericitabine and ritonavir‐boosted danoprevir
Number of subjects: 72
Study 25118055 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eligible patients
Number of subjects: 332
Study 25118055 — intervention group
Group type: COMPARATOR
Intervention: Eligible non-randomized patients
Number of subjects: 332
Study 25118055 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eligible patients (adjusted)
Number of subjects: 332
Study 25118055 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eligible patients (further adjusted)
Number of subjects: 332
Study 21689927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800mg QD
Number of subjects: 435
Study 21689927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 19614805 — intervention group
Group type: EXPERIMENTAL
Intervention: T80 mg plus A10 mg
Number of subjects: 1461
Study 19614805 — intervention group
Group type: COMPARATOR
Intervention: A10 mg
Number of subjects: 1461
Study 19614805 — intervention group
Group type: EXPERIMENTAL
Intervention: T20/A10
Number of subjects: 1461
Study 19614805 — intervention group
Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 1461
Study 19614805 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 1461
Study 17888133 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 27
Study 17888133 — intervention group
Group type: COMPARATOR
Intervention: Regular Human Insulin (HI)
Number of subjects: 27
Study 15173858 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg m(‐2) plus Paclitaxel 200 mg m(‐2) (3‐h infusion) on day 1 every 3 weeks for eight courses (arm A)
Number of subjects: 0
Study 15173858 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 120 mg m(‐2) on day 1 every 3 weeks for four courses followed by four courses of Paclitaxel 250 mg m(‐2) on day 1 every 3 weeks (arm B)
Number of subjects: 0
Study 12473876 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic health counselling given by local public health nurses for 2 years
Number of subjects: 715
Study 12473876 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants with antihypertensive drug treatment)
Number of subjects: 715
Study 10408330 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 25
Study 10408330 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 25
Study 10408330 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 7802586 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum range of motion cohort (shoulder immobilization)
Number of subjects: 38
Study 7802586 — intervention group
Group type: COMPARATOR
Intervention: Minimum range of motion cohort (no shoulder immobilization)
Number of subjects: 38
Study 2366542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gripping the cycle ergometer handlebar
Number of subjects: 39
Study 2366542 — intervention group
Group type: COMPARATOR
Intervention: Not gripping the cycle ergometer handlebar
Number of subjects: 39
Study 6986149 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-thiopyridoxine (5-TP)
Number of subjects: 60
Study 6986149 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 60
Study 6986149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic music video (TMV) intervention
Number of subjects: 14
Study 31787055 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal LAD angioplasty
Number of subjects: 17805
Study 31787055 — intervention group
Group type: COMPARATOR
Intervention: Nonproximal LAD angioplasty
Number of subjects: 17805
Study 27136962 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC) after Endoscopic Variceal Ligation (EVL)
Number of subjects: 40
Study 27136962 — intervention group
Group type: COMPARATOR
Intervention: Observation after Endoscopic Variceal Ligation (EVL)
Number of subjects: 40
Study 25839203 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbors of buyers who ordered and received a stove
Number of subjects: 0
Study 25839203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prominent community member using the efficient stove
Number of subjects: 0
Study 25839203 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer effects in opinions about efficient cookstoves
Number of subjects: 0
Study 25492279 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple primary closure
Number of subjects: 60
Study 25492279 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid flap
Number of subjects: 60
Study 25492279 — intervention group
Group type: COMPARATOR
Intervention: Lay open group
Number of subjects: 60
Study 22630163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 76
Study 22630163 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 76
Study 19174586 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact, nonthermal, low-frequency ultrasound therapy
Number of subjects: 11
Study 19174586 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study 19174586 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver antimicrobial dressings
Number of subjects: 11
Study 19174586 — intervention group
Group type: COMPARATOR
Intervention: Water-moistened gauze
Number of subjects: 11
Study 17380588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet (250, 500, 750, or 1000 microg)
Number of subjects: 32
Study 17380588 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 32
Study 15974642 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12
Study 15974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil
Number of subjects: 12
Study 15974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 12
Study 15974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 12
Study 12489490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 36 mg)
Number of subjects: 2500
Study 12489490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 24 mg daily)
Number of subjects: 2500
Study 12489490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 12489490 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous LMW heparin followed by warfarin
Number of subjects: 2500
Study 9807844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuplaster (BL-10, BL-11, GB-34)
Number of subjects: 65
Study 9807844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7630652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Cranking (AC)
Number of subjects: 9
Study 7630652 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Propulsion on Treadmill (TM)
Number of subjects: 9
Study 2488091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (BEP, n = 100)
Number of subjects: 200
Study 2488091 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN, n = 100)
Number of subjects: 200
Study 36865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium amobarbital interview
Number of subjects: 20
Study 36865 — intervention group
Group type: COMPARATOR
Intervention: Saline interview (placebo)
Number of subjects: 20
Study 30810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg
Number of subjects: 188
Study 30810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg
Number of subjects: 188
Study 30810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg
Number of subjects: 188
Study 30810754 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-opioid medications)
Number of subjects: 188
Study 28750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled AP301
Number of subjects: 40
Study 28750677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 40
Study 26378637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin 350 mg/m2
Number of subjects: 126
Study 26378637 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2
Number of subjects: 126
Study 23514733 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 0.6 mg
Number of subjects: 0
Study 23514733 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 18 mg
Number of subjects: 0
Study 23514733 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102 180 mg
Number of subjects: 0
Study 23514733 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189102
Number of subjects: 0
Study 23514733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19575143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - 10 min of ischemia followed by 15 min of reperfusion before SHVE
Number of subjects: 84
Study 19575143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 84
Study 19575143 — intervention group
Group type: COMPARATOR
Intervention: Selective hepatic vascular exclusion (SHVE) - control group
Number of subjects: 84
Study 16466554 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective laparoscopically assisted resection
Number of subjects: 48
Study 16466554 — intervention group
Group type: EXPERIMENTAL
Intervention: Open resection
Number of subjects: 48
Study 16466554 — intervention group
Group type: COMPARATOR
Intervention: Nonmalignant colonic disease (control group)
Number of subjects: 48
Study 16676777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 332
Study 16676777 — intervention group
Group type: COMPARATOR
Intervention: Dysfunctional Beliefs and Attitudes about Sleep scale (DBAS)
Number of subjects: 332
Study 14504122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day quadruple therapy (4-drug regimen)
Number of subjects: 160
Study 14504122 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy (3-drug regimen)
Number of subjects: 160
Study 14504122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 10802469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 2 mL per hour
Number of subjects: 62
Study 10802469 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion at 2 mL per hour
Number of subjects: 62
Study 8874303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg, maximum dose 10 mg)
Number of subjects: 66
Study 8874303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 66
Study 8874303 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 66
Study 1997811 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up (WU)
Number of subjects: 6
Study 1997811 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 6
Study 6298318 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir applied six times daily for five days
Number of subjects: 88
Study 6298318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29273207 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 404
Study 29273207 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel, placebo)
Number of subjects: 404
Study 28329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon add-on therapy (n = 39)
Number of subjects: 77
Study 28329061 — intervention group
Group type: COMPARATOR
Intervention: NA monotherapy (n = 38)
Number of subjects: 77
Study 28329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon add-on therapy (among 58 interferon-naive patients)
Number of subjects: 77
Study 28329061 — intervention group
Group type: COMPARATOR
Intervention: NA monotherapy (among 58 interferon-naive patients)
Number of subjects: 77
Study 28329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders at week 48 who discontinued NA therapy at week 72 (n = 8)
Number of subjects: 77
Study 28329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on therapy group (n = 6)
Number of subjects: 77
Study 28329061 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group (n = 2)
Number of subjects: 77
Study 26161399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute walk in a city park for 7 consecutive days
Number of subjects: 20
Study 26161399 — intervention group
Group type: COMPARATOR
Intervention: 30-minute walk on a busy urban street for 7 consecutive days
Number of subjects: 20
Study 23287811 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 286
Study 23287811 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting to be treated)
Number of subjects: 286
Study 21215350 — intervention group
Group type: EXPERIMENTAL
Intervention: CB‐CIK + Chemotherapy
Number of subjects: 40
Study 21215350 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40
Study 18792997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (ESWT)
Number of subjects: 68
Study 18792997 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic dose treatment
Number of subjects: 68
Study 16421419 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 administered every 2 weeks until progression (arm A)
Number of subjects: 620
Study 16421419 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 620
Study 15522768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild head injury (MHI)
Number of subjects: 16
Study 15522768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MHI)
Number of subjects: 16
Study 11284542 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% SCN‐/0.1% H2O2 (group E)
Number of subjects: 140
Study 11284542 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% H2O2 (group F)
Number of subjects: 140
Study 11284542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 140
Study 9364996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9364996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 13
Study 8324432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (0.8 mg of folic acid)
Number of subjects: 4156
Study 8324432 — intervention group
Group type: COMPARATOR
Intervention: Trace elements supplement
Number of subjects: 4156
Study 3087241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram X kg‐1 X min‐1)
Number of subjects: 81
Study 3087241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29356602 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes sleep education program
Number of subjects: 31
Study 29356602 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 27625060 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (observation prior to discharge)
Number of subjects: 342
Study 27625060 — intervention group
Group type: COMPARATOR
Intervention: Interventional management (insertion of a small bore drain)
Number of subjects: 342
Study 27625060 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 342
Study 27625060 — intervention group
Group type: COMPARATOR
Intervention: Interventional management
Number of subjects: 342
Study 24865441 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual multimodal screening
Number of subjects: 23374
Study 24865441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 23374
Study 24865441 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level repeat screening
Number of subjects: 23374
Study 24865441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer surgery
Number of subjects: 23374
Study 24865441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 23374
Study 21667290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 45% (easy) intensity
Number of subjects: 14
Study 21667290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 60% (moderate) intensity
Number of subjects: 14
Study 21667290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of exercises at 75% (vigorous) intensity
Number of subjects: 14
Study 21667290 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min of moderate exercises
Number of subjects: 14
Study 21667290 — intervention group
Group type: EXPERIMENTAL
Intervention: 30, 60, and 90 min of moderate exercises
Number of subjects: 14
Study 21667290 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 14
Study 20640403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal anchors (group 1)
Number of subjects: 78
Study 20640403 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable anchors (group 2)
Number of subjects: 78
Study 18824608 — intervention group
Group type: EXPERIMENTAL
Intervention: BILR 355 alone (12.5 mg to 100 mg)
Number of subjects: 0
Study 18824608 — intervention group
Group type: EXPERIMENTAL
Intervention: BILR 355 with ritonavir (RTV) (5 mg to 87.5 mg)
Number of subjects: 0
Study 18824608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19116439 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric push-ups
Number of subjects: 12
Study 19116439 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine-ball chest passes
Number of subjects: 12
Study 19116439 — intervention group
Group type: COMPARATOR
Intervention: First trial (no explosive movement)
Number of subjects: 12